| Literature DB >> 12600650 |
Louise Cooley1, Joseph Sasadeusz.
Abstract
The improved prognosis of HIV-infection that has occurred since the introduction of highly active antiretroviral therapy (HAART) has resulted in renewed emphasis being placed on co-morbidities associated with HIV-infection, and chronic viral hepatitis in particular. Hepatitis B virus (HBV) infection is an important infection in HIV-1 infected individuals because of the influence of HIV-1 co-infection on the natural history of HBV infection. Antiviral therapies with activity against both viruses have enabled targeted therapy in co-infected individuals, however, optimism regarding improved prognosis has been tempered by the development of antiviral resistant HBV. Emerging new classes of HBV therapies herald the possibility of combination HBV therapy. Copyright 2002 Elsevier Science B.V.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12600650 DOI: 10.1016/s1386-6532(02)00117-8
Source DB: PubMed Journal: J Clin Virol ISSN: 1386-6532 Impact factor: 3.168